Response Biomedical Hits Key Milestone in 3M Collaboration for Infection Prevention

24-Aug-2005

Response Biomedical Corp. announced that it has met a key development milestone as part of the co-development agreement with 3M Health Care announced on November 29, 2004. Under the agreement, 3M Health Care is funding the development of a new rapid, point-of-care microbiology test in the area of infection prevention based on Response Biomedical's RAMP technology. This collaboration is aimed at introducing a product portfolio to improve the outcome of patients entering the hospital system.

"Hospital acquired infections are a tremendous burden on the health care system costing almost US$10 billion per year in the US alone, and result in approximately 12,000 deaths annually," stated Bill Radvak, President & CEO.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances